Defunct Company
Total Trials
7
As Lead Sponsor
5
As Collaborator
2
Total Enrollment
238
NCT02657005
TK216 in Patients With Relapsed or Refractory Ewing Sarcoma
Phase: Phase 1/2
Role: Lead Sponsor
Start: Aug 31, 2016
Completion: Jun 30, 2022
NCT03088878
A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies
Start: Jan 3, 2018
Completion: Sep 25, 2024
NCT02776917
Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer
Phase: Phase 1
Role: Collaborator
Start: Aug 15, 2018
Completion: Feb 26, 2024
NCT04501939
Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax
Phase: Phase 2
Start: Aug 6, 2020
Completion: Jul 22, 2026
NCT05431179
A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Phase: Phase 3
Start: Mar 31, 2023
Completion: Dec 31, 2026
NCT05588440
A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies
Start: May 9, 2023
Completion: Sep 12, 2024
NCT05917470
A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.
Start: Sep 20, 2023